China’s stricter air quality standards can avert over 200,000 deaths

China introduced a 35 µg m⁻³ annual PM₂.₅ limit in 2012 and later cut population-weighted exposure from 62.8 to 29.7 µg m⁻³ between 2013 and 2024 through clean air actions. Yet major economies and the World Health Organization (WHO) have adopted stricter guidelines, and China’s “Beautiful China Initiative” targets below 25 µg m⁻³ by 2035. In 2026, China revised its National Ambient Air Quality Standards (NAAQS) to 25 µg m⁻³, with an interim 30 micrograms per cubic meter (µg m⁻³) phase from 2026 to 2030. Questions remain about how much this revision improves health, which diseases gain most, and how far it advances the WHO 2040 halving target. Given these challenges, deeper research is needed into the disease-specific health benefits and residual burdens of stricter particulate matter (PM_2.5) standards.

A study (DOI: 10.1016/j.ese.2026.100781) by researchers at Peking University Health Science Center and the Chinese Academy of Environmental Planning was published online 23 October 2026 in Environmental Science and Ecotechnology. The team integrated high-resolution PM_2.5 data, gridded population estimates and disease-specific exposure–response functions to quantify PM_2.5-attributable deaths across mainland China from 2013 to 2024 and under full-compliance scenarios for 35, 30 and 25 µg m⁻³. The analysis covered seven disease outcomes in the Global Burden of Disease (GBD) 2023 risk set.

In 2024, full compliance with the 25 µg m⁻³ standard would have averted an estimated 233,668 premature deaths (95% uncertainty interval [UI]: 198,354–270,734), a 16.1% reduction from observed levels, compared with 53,985 avoided deaths (95% UI: 45,992–62,021) under the 35 µg m⁻³ standard. The stricter limit would expand the population above the regulatory threshold from 33% to 65%. Health gains were strongly disease-specific: under the 25 µg m⁻³ scenario, mortality fell by 22.8% for chronic obstructive pulmonary disease (COPD), 18.4% for stroke, 18.4% for lung cancer, 18.0% for lower respiratory infections (LRI) and 16.0% for ischemic heart disease (IHD). Reductions were only 1.4% for dementia and 1.1% for type 2 diabetes mellitus (T2DM); the dementia estimate requires caution because evidence is weaker. Nationally, the PM_2.5-attributable fraction of mortality fell from 32.5% in 2015 to 22.6% in 2024. Full compliance with 35, 30 and 25 µg m⁻³ would increase PM_2.5-specific progress toward the WHO halving target to 66.2%, 72.6% and 83.4%, respectively. COPD would exceed the 50% halving benchmark under the 25 µg m⁻³ scenario, whereas dementia and T2DM would remain far behind. A sensitivity analysis using the Global Exposure Mortality Model (GEMM) for non-communicable diseases and LRI showed a similar pattern, with 3.9 times more deaths averted under 25 than 35 µg m⁻³.

The results support health-oriented implementation of China’s revised NAAQS. Policymakers could prioritize regions with large populations and high PM_2.5 exposure, where compliance with 25 µg m⁻³ would yield the largest gains, and pair air-quality control with older-adult protection, clinical prevention and chronic-disease management. Because abatement costs are rising and population aging can offset exposure-related gains, future standards should be evaluated by disease-specific health returns, not compliance rates alone. The framework could inform other developing countries seeking to tighten PM₂.₅ limits while tracking progress toward the WHO 2040 halving target.